|
Jan 9
|
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
|
|
Dec 8
|
Skye Bioscience Responds to OTC Markets Promotional Policy
|
|
Dec 5
|
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
|
|
Nov 28
|
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
|
|
Aug 21
|
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
|
|
Jul 6
|
Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
|